{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:18Z","timestamp":1793502918061,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00198-016-3647-y","type":"journal-article","created":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T04:14:35Z","timestamp":1464754475000},"page":"3301-3307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Teriparatide and denosumab combination therapy and skeletal metabolism"],"prefix":"10.1007","volume":"27","author":[{"given":"L.","family":"Idolazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Braga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fassio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Benini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kunnathully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Adami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,1]]},"reference":[{"key":"3647_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","volume":"24","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 24:23\u201357. doi:\n10.1007\/s00198-012-2074-y","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"3647_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165\u2013176","journal-title":"Cell"},{"key":"3647_CR3","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1210\/endo.141.12.7921","volume":"141","author":"JE Fisher","year":"2000","unstructured":"Fisher JE, Rodan GA, Reszka AA (2000) In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 141:4793\u20134796. doi:\n10.1210\/endo.141.12.7921","journal-title":"Endocrinology"},{"key":"3647_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00198-007-0475-0","volume":"19","author":"F Cosman","year":"2008","unstructured":"Cosman F, Nieves JW, Zion M et al (2008) Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 19:529\u2013535. doi:\n10.1007\/s00198-007-0475-0","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"3647_CR5","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","volume":"18","author":"Y Jiang","year":"2003","unstructured":"Jiang Y, Zhao JJ, Mitlak BH et al (2003) Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res Off J Am Soc Bone Miner Res 18:1932\u20131941. doi:\n10.1359\/jbmr.2003.18.11.1932","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"3647_CR6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1359\/jbmr.060314","volume":"21","author":"YL Ma","year":"2006","unstructured":"Ma YL, Zeng Q, Donley DW et al (2006) Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res Off J Am Soc Bone Miner Res 21:855\u2013864. doi:\n10.1359\/jbmr.060314","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"3647_CR7","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","volume":"16","author":"DW Dempster","year":"2001","unstructured":"Dempster DW, Cosman F, Kurland ES et al (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res Off J Am Soc Bone Miner Res 16:1846\u20131853. doi:\n10.1359\/jbmr.2001.16.10.1846","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"3647_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1359\/jbmr.061011","volume":"22","author":"TM Keaveny","year":"2007","unstructured":"Keaveny TM, Donley DW, Hoffmann PF et al (2007) Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res Off J Am Soc Bone Miner Res 22:149\u2013157. doi:\n10.1359\/jbmr.061011","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"3647_CR9","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1210\/jc.2010-2552","volume":"96","author":"D Gatti","year":"2011","unstructured":"Gatti D, Viapiana O, Idolazzi L et al (2011) The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab 96:1555\u20131559. doi:\n10.1210\/jc.2010-2552","journal-title":"J Clin Endocrinol Metab"},{"key":"3647_CR10","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1359\/JBMR.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res Off J Am Soc Bone Miner Res 19:745\u2013751. doi:\n10.1359\/JBMR.040117","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"3647_CR11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/NEJMoa050157","volume":"353","author":"F Cosman","year":"2005","unstructured":"Cosman F, Nieves J, Zion M et al (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566\u2013575. doi:\n10.1056\/NEJMoa050157","journal-title":"N Engl J Med"},{"key":"3647_CR12","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/jc.2007-0711","volume":"93","author":"S Boonen","year":"2008","unstructured":"Boonen S, Marin F, Obermayer-Pietsch B et al (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852\u2013860. doi:\n10.1210\/jc.2007-0711","journal-title":"J Clin Endocrinol Metab"},{"key":"3647_CR13","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1210\/jc.2008-0353","volume":"93","author":"PD Miller","year":"2008","unstructured":"Miller PD, Delmas PD, Lindsay R et al (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785\u20133793. doi:\n10.1210\/jc.2008-0353","journal-title":"J Clin Endocrinol Metab"},{"key":"3647_CR14","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1210\/jc.2008-2719","volume":"94","author":"F Cosman","year":"2009","unstructured":"Cosman F, Wermers RA, Recknor C et al (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 94:3772\u20133780. doi:\n10.1210\/jc.2008-2719","journal-title":"J Clin Endocrinol Metab"},{"key":"3647_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jbmr.238","volume":"26","author":"F Cosman","year":"2011","unstructured":"Cosman F, Eriksen EF, Recknor C et al (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res Off J Am Soc Bone Miner Res 26:503\u2013511. doi:\n10.1002\/jbmr.238","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"3647_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","volume":"382","author":"JN Tsai","year":"2013","unstructured":"Tsai JN, Uihlein AV, Lee H et al (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet Lond Engl 382:50\u201356. doi:\n10.1016\/S0140-6736(13)60856-9","journal-title":"Lancet Lond Engl"},{"key":"3647_CR17","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","volume":"99","author":"BZ Leder","year":"2014","unstructured":"Leder BZ, Tsai JN, Uihlein AV et al (2014) Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab 99:1694\u20131700. doi:\n10.1210\/jc.2013-4440","journal-title":"J Clin Endocrinol Metab"},{"key":"3647_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00223-013-9749-z","volume":"93","author":"M Rossini","year":"2013","unstructured":"Rossini M, Gatti D, Adami S (2013) Involvement of WNT\/\u03b2-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93:121\u2013132. doi:\n10.1007\/s00223-013-9749-z","journal-title":"Calcif Tissue Int"},{"key":"3647_CR19","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1210\/en.2007-0270","volume":"148","author":"R Baron","year":"2007","unstructured":"Baron R, Rawadi G (2007) Targeting the Wnt\/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148:2635\u20132643. doi:\n10.1210\/en.2007-0270","journal-title":"Endocrinology"},{"key":"3647_CR20","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.1210\/jc.2005-2370","volume":"90","author":"SM Ott","year":"2005","unstructured":"Ott SM (2005) Sclerostin and Wnt signaling\u2014the pathway to bone strength. J Clin Endocrinol Metab 90:6741\u20136743. doi:\n10.1210\/jc.2005-2370","journal-title":"J Clin Endocrinol Metab"},{"key":"3647_CR21","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1002\/jbmr.1681","volume":"27","author":"D Gatti","year":"2012","unstructured":"Gatti D, Viapiana O, Fracassi E et al (2012) Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res Off J Am Soc Bone Miner Res 27:2259\u20132263. doi:\n10.1002\/jbmr.1681","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"3647_CR22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res Off J Am Soc Bone Miner Res 8:1137\u20131148. doi:\n10.1002\/jbmr.5650080915","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"3647_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1359\/jbmr.2003.18.3.539","volume":"18","author":"JR Zanchetta","year":"2003","unstructured":"Zanchetta JR, Bogado CE, Ferretti JL et al (2003) Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res Off J Am Soc Bone Miner Res 18:539\u2013543. doi:\n10.1359\/jbmr.2003.18.3.539","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"3647_CR24","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1210\/jc.2015-3698","volume":"101","author":"F Cosman","year":"2016","unstructured":"Cosman F, Dempster DW, Nieves JW et al (2016) Effect of teriparatide on bone formation in the human femoral neck. J Clin Endocrinol Metab 101:1498\u20131505. doi:\n10.1210\/jc.2015-3698","journal-title":"J Clin Endocrinol Metab"},{"key":"3647_CR25","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1210\/jc.2015-4181","volume":"101","author":"DW Dempster","year":"2016","unstructured":"Dempster DW, Zhou H, Recker RR et al (2016) Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study. J Clin Endocrinol Metab 101:1353\u20131363. doi:\n10.1210\/jc.2015-4181","journal-title":"J Clin Endocrinol Metab"},{"key":"3647_CR26","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","volume":"15","author":"P Garnero","year":"2000","unstructured":"Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res Off J Am Soc Bone Miner Res 15:1526\u20131536. doi:\n10.1359\/jbmr.2000.15.8.1526","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"3647_CR27","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1210\/jc.2007-1508","volume":"93","author":"KK Ivaska","year":"2008","unstructured":"Ivaska KK, Lenora J, Gerdhem P et al (2008) Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk. J Clin Endocrinol Metab 93:2622\u20132632. doi:\n10.1210\/jc.2007-1508","journal-title":"J Clin Endocrinol Metab"},{"key":"3647_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.bone.2011.11.028","volume":"50","author":"D Gatti","year":"2012","unstructured":"Gatti D, Viapiana O, Adami S et al (2012) Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50:739\u2013742. doi:\n10.1016\/j.bone.2011.11.028","journal-title":"Bone"},{"key":"3647_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1196\/annals.1346.015","volume":"1068","author":"DA Glass","year":"2006","unstructured":"Glass DA, Karsenty G (2006) Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation. Ann N Y Acad Sci 1068:117\u2013130. doi:\n10.1196\/annals.1346.015","journal-title":"Ann N Y Acad Sci"},{"key":"3647_CR30","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","volume":"8","author":"DA Glass","year":"2005","unstructured":"Glass DA, Bialek P, Ahn JD et al (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751\u2013764. doi:\n10.1016\/j.devcel.2005.02.017","journal-title":"Dev Cell"},{"key":"3647_CR31","doi-asserted-by":"publisher","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","volume":"6","author":"AR Wijenayaka","year":"2011","unstructured":"Wijenayaka AR, Kogawa M, Lim HP et al (2011) Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 6:e25900. doi:\n10.1371\/journal.pone.0025900","journal-title":"PLoS One"},{"key":"3647_CR32","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1242\/jcs.02883","volume":"119","author":"GJ Spencer","year":"2006","unstructured":"Spencer GJ, Utting JC, Etheridge SL et al (2006) Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 119:1283\u20131296. doi:\n10.1242\/jcs.02883","journal-title":"J Cell Sci"},{"key":"3647_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1476-4598-6-71","volume":"6","author":"K Fujita","year":"2007","unstructured":"Fujita K, Janz S (2007) Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 6:71. doi:\n10.1186\/1476-4598-6-71","journal-title":"Mol Cancer"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-016-3647-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-016-3647-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-016-3647-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T13:47:58Z","timestamp":1493387278000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-016-3647-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,1]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["3647"],"URL":"https:\/\/doi.org\/10.1007\/s00198-016-3647-y","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,1]]}}}